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Abstract Factor X (FX) deﬁciency is a rare hered-
itary coagulation disorder. This is the ﬁrst case report
on the association of FX deﬁciency and membrano-
proliferative glomerulonephritis (MPGN) type I. The
patient, a 17-year-old male, presented with edema,
hypertension, and microscopic hematuria, followed
by a mild upper respiratory tract infection. Labora-
tory tests revealed: serum creatinine 1.6 mg/dl, serum
albumin 2.80 g/dl, C3 16 mg/dl and proteinuria
(1,800 mg/day). The renal biopsy showed MPGN
type I. The coagulation proﬁle prior to percutaneous
renal biopsy revealed prolonged prothrombin time
and activated partial thromboplastin time values. The
patient was given fresh frozen plasma and vitamin K
before the biopsy. Further evaluation showed the
functional activity of FX was 7% of the norm. This
case emphasizes the need for routine coagulation
screening before percutaneous renal biopsy.
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Introduction
Congenital factor X deﬁciency is an extremely rare
autosomal recessive disorder affecting both genders
with an incidence of 1:500.000–1.000.000. An even
more uncommon situation of acquired deﬁciency of
factor X activity has also been described in addition
to the inherited deﬁciency. This occasionally occurs
in patients with liver diseases, vitamin K deﬁciency,
amyloidosis, multiple myeloma, mycoplasma pneu-
moniae infection, leprosy and methyl bromide expo-
sure [1–5].
The normal FX plasma levels are 8–10 lg/ml.
Half-life in plasma is 34–40 h. This factor plays a
crucial role in the coagulation cascade. It is activated
either by factor VIIa/TF (tissue factor) complex via
extrinsic pathway or by IXa/VIIIa complex via
intrinsic pathway. The functional activity of factor
X required for surgical hemostasis is 10–40% of the
normal activity. Patients with mild to moderate
deﬁciency remain asymptomatic until stressed by
trauma or surgery. Subclinical coagulation disorders
that are not evident from the patient’s clinical history
and examination could only be revealed by biochem-
ical assessment [2, 6, 7].
The association of FX deﬁciency with membrano-
proliferative glomerulonephritis (MPGN) has never
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associated with asymptomatic mild FX deﬁciency and
abnormal coagulation tests, discovered before the
percutaneous renal biopsy. This case emphasizes the
need for routine coagulation screening in patients
undergoing percutaneous renal biopsy.
Case report
The patient, a 17-year-old male, presented with
edema, hypertension and microscopic hematuria,
followed by a mild upper respiratory tract infection.
Laboratory work-up revealed an elevated serum
creatinine (1.6 mg/dl, normal range: 0.5–1.2 mg/dl),
a decreased serum albumin (2.80 g/dl, normal range:
3.5–5.2 g/dl), a low serum complement component 3
(C3) (16 mg/dl, normal range: 85–200 mg/dl) and
proteinuria (1,800 mg/day, normal range: 0–150 mg/
dl). Serology was negative for antinuclear, anti-
double stranded DNA and anti-neutrophil cytoplas-
mic antibodies. A renal biopsy was therefore
indicated.
The patient was found to have prolonged pro-
thrombin time (PT) (22.2 s-control 10–14 s) and
activated partial thrombin time (aPTT) (43.8 s-con-
trol 26–40 s). The patient’s clinical history was not
suggestive for coagulation disorders (i.e. no bruising,
nosebleed, hematoma or excess bleeding after minor
trauma or neurological deﬁcits). There was no history
of fever, jaundice or exposure to toxic substances or
drugs interfering with coagulation or platelet function
either. There was also no family history of bleeding
disorders. On physical examination, we found no
purpura, joint swelling or organomegaly.
Percutaneous renal biopsy was performed after
fresh frozen plasma (15–20 ml/kg) and vitamin K
(20 mg) administration. The only complication
encountered was the development of macroscopic
hematuria 10 days after the biopsy.
Further investigations revealed normal liver func-
tion. Subsequently, FX, FII and FV activity tests were
performed revealing FX activity to be 7%, FII
activity 130% and FV activity 94% (reference range:
70–120%) of the norms.
The patients’ family evaluation found the PT and
aPTT in his mother and in one of his sisters were in
normal range, while his father, another sister and two
brothers had prolonged coagulation times. The FX
activity in the father, the second sister and the two
brothers were 18, 8, 12 and 9% of the norm,
respectively. The other factors of the coagulation
cascade were normal in all family members.
Subsequent genetic study in the patient and his
family members with FX deﬁciency revealed a
homozygous Glu310Lys mutation in exon 8 of the
FX gene (Fig. 1).
The patient’s renal biopsy showed MPGN Type I.
He was subsequently treated with prednisolone,
omeprazole, and angiotensin-converting enzyme
inhibitors. At the end of the ﬁrst year of treatment,
the patient showed improved serum creatinine (1 mg/
dl) and serum albumin (4.0 g/dl) and a signiﬁcant
reduction in proteinuria (200 mg/day). Meanwhile,
the coagulation tests (PT:18.6 s, aPTT:38.2 s) and the
FX activity level (10%) did not change signiﬁcantly
(Table 1).
Discussion
Factor X, also known as the Stuart-Prower factor, is a
vitamin K-dependent serine protease that serves as
the ﬁrst enzyme in the common pathway of thrombus
formation. The FX gene is 22 kb-long and is located
at 13q34-ter, 2.8 kb downstream from the factor VII
gene. Because of the central role of this factor in the
clotting cascade, the complete absence of FX is
lethal. Hence, mutations of factor X are thought to be
rare, although approximately 71 different types have
been reported [2, 10].
The bleeding tendency of factor X deﬁciency is
severe and correlates with factor levels. People can
suffer from bleeding when the FX level falls below
10% of normal. As a general rule, patients with FX
activity levels above 10% are asymptomatic, those
with FX levels in the range of 1 to 10% present with
mild or moderate bleeding, whereas those with FX
levels below 1% experience severe bleeding. The
most common reported spontaneous bleeding symp-
tom is epistaxis but gastrointestinal bleeding,
hemarthrosis, menorrhagia, hematuria, soft tissue
bleeding and umbilical cord bleeding have also
been reported. Mild deﬁciency (plasma FX levels
between 6–10 IU/dl) may be identiﬁed only during
family studies [8, 9].
The prevalence of FX deﬁciency is greater among
populations in which consanguineous marriage is
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bleeding tendency, most severely affecting homozy-
gous patients. Heterozygous patients, who are usually
clinically asymptomatic, may also experience
signiﬁcant bleeding due to insufﬁcient enzymatic
activity caused by wild-type factor X or the inhibition
of one of the reactions in the coagulation pathway by a
mutant protein. A dysfunctional factor Xa molecule
Fig. 1 Results of the mutation analysis for the family and patient
Table 1 Clinical and
biochemical parameters of
the patient
Parameters Baseline The end of
the ﬁrst year
Systolic vs. diastolic blood pressure (\120/80 mmHg) 150/100 110/70
Serum creatinine (normal range: 0.5–1.2 mg/dl) 1.6 1.0
Serum albumin (normal range: 0.5–1.2 mg/dl) 2.80 4.00
C3 complement level (normal range: 85–200 mg/dl) 16 58
Prothrombin time (control 10–14 s) 22.2 18.6
Activated partial thrombin time (control 26–40 s) 43.8 38.2
Factor X activity (reference range: 70–120%) 7% 10%
Proteinuria (g/24 h)(normal range: 0–150 mg/dl) 1,800 200
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123may compete with its normal counterpart to form a
complexwithprothrombinandreducetheformationof
an active prothrombinase complex [10, 11].
The PT and the aPTT are prolonged in patients
with FX deﬁciency. The Russell viper venom time is
also prolonged in these patients; (Russell viper
venom cleaves factor X to produce active factor
Xa). Bleeding time is within the reference range in
patients with factor X deﬁciency. The diagnosis can
be conﬁrmed by measuring the plasma FX levels. The
following assays for this measurement are available:
(1) the one-stage PT- and aPTT-based assays; (2) a
chromogenic assay; (3) the Russell viper venom
assay; and (4) an immunological assay (such as an
enzyme-linked immunosorbent assay). The PT- and
aPTT-based assays are usually sufﬁcient for diagno-
sis, and further tests are required only for detailed
protein characterization [2, 10].
There is no general agreement in guidelines for the
management of FX deﬁciency. The treatment has an
individual approach for each patient. However,
restoring circulating FX levels to 10–40% of normal
is usually adequate. Therapy involves replacement of
FX with either fresh frozen plasma or prothrombin
complex concentrates. Fresh frozen plasma does not
contain adequate quantities of FX and is usually
given when speciﬁc replacement therapy is not
available. Virally inactivated plasma should be used
at a dose of 20 ml/kg followed by 3–6 ml/kg twice
daily, aiming to keep the trough levels of FX higher
than 10–20 IU/dl. Recombinant FVIIa has been used
in adults to treat amyloidosis-related FX deﬁciency,
but there is no evidence supporting its use in patients
with hereditary FX deﬁciencies [12].
Prothrombin complex concentrate has been used
as a regular prophylaxis in these patients. Authors of
one report described using 30 U/kg twice weekly as a
home treatment. If breakthrough bleeding occurred,
another dose was administered, but not more than two
doses within 24 h or 3 consecutive days. However,
there is a risk of thromboembolic complication when
2–3 standard doses are administered in 48 h [13].
Vitamin K administration may be useful in certain
patients with acquired FX deﬁciency. Patients with
inherited deﬁciency do not respond to vitamin K
administration and, in fact, this lack of response helps
to establish the diagnosis of this disorder [2].
The prognosis for patients with FX deﬁciency
depends on the etiology and severity of the disease.
While acquired FX deﬁciency may be eliminated by
treating the underlying cause, the congenital form of
the disease is lifelong and is among the most severe
clotting factor disorders. In general, patients with
very low levels of functional FX have a greater
tendency to hemorrhage and face a greater risk of
life-threatening complications [14, 15].
On the other hand, we know that tissue factor
initiates the extrinsic coagulation pathway by activat-
ing coagulation factor X to factor Xa, and Xa factor is
known to promote the proliferation of mesangial cells
in culture. In animal models, DX-9065a, a speciﬁc Xa
factor inhibitor, proved to reduce proteinuria and to
signiﬁcantly reduce the size of glomeruli, the total
numberofglomerularcellsandcrescentformation.So,
factorXdeﬁciency shouldmodifytheevolutionofthis
proliferative GN [16–18].
Conclusions
Although the patient had no personal or family history
suggestive of coagulation disorder, routine screening
revealed abnormal PT and aPTT. Therefore, normal
clinical history and physical examination do not
exclude mild to moderate coagulation disorders.
Although the incidence of FX deﬁciency is rare,
this diagnosis should be considered when patients
present with bleeding diathesis or abnormal coagu-
lation tests. Coagulation testing before performing
percutaneous renal biopsy is very important, as
demonstrated by this case.
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